Neuropathy in Cancer: How Common, Why It Happens, and How It’s Managed

Neuropathy (nerve damage causing numbness, tingling, burning pain, or weakness) is relatively common in people undergoing cancer treatment and can sometimes be linked to the cancer itself. Anti‑cancer therapy–induced peripheral neuropathy is a frequent, dose‑related side effect that may limit treatment and affect quality of life. ^[1] Across agents, roughly one‑third of people exposed to multiple neurotoxic drugs can develop neuropathy, though risks vary by drug, dose, and duration. ^[2]

---

What neuropathy feels like

• Typical pattern: symmetrical “glove and stocking” sensory symptoms in fingers and toes that may spread to hands and feet. ^[3]
• Range of severity: mild tingling to severe pain, numbness, balance problems, or weakness; onset can be sudden or progressive. ^[4]
• Impact on daily life: can lead to treatment dose reductions, delays, or discontinuation when severe. ^[1]

---

How common is it?

Prevalence depends on the treatment:

• Vinca alkaloids: neuropathy in about 20% of patients; vincristine may reach ~30–40%, especially at higher cumulative doses. ^[5]
• Taxanes, platins, and other neurotoxic drugs: widely used and well‑known to cause CIPN; risk is cumulative over weeks. ^[1] Onset often occurs after several weeks, but can appear after the first dose. ^[6]
• Antibody‑drug conjugates (ADCs): several agents (e.g., enfortumab vedotin) commonly cause sensory neuropathy; median onset around 2–3 months and most cases are mild‑to‑moderate. ^[7]
• Some agents (e.g., lenalidomide): appear to have less substantial neurotoxicity overall. ^[8]

---

Why neuropathy happens

• Drug‑related nerve injury: anti‑cancer drugs can inflame, injure, or degenerate peripheral nerve fibers, affecting sensory, motor, or cranial nerves. ^[4]
• Dose and accumulation: risk is often dose‑related and cumulative with repeated cycles. ^[1]
• Mechanisms vary by drug: for example, taxanes disrupt microtubules and axonal transport; other agents can impair mitochondrial function in sensory neurons. [PM19]

---

When neuropathy starts and how it evolves

• Onset: commonly after several weeks of therapy; occasionally after the first dose. ^[6]
• Course: may worsen with ongoing exposure; higher exposure increases the likelihood of moderate or worse neuropathy. ^[7]
• Recovery: symptoms can improve with dose reduction or treatment pause; some cases only partially reverse after stopping therapy. ^[8] Many cases resolve over follow‑up, though a subset can be persistent. ^[7]

---

Red flags and when to call your team

• New or worsening numbness, tingling, burning pain, or weakness in hands/feet. ^[3]
• Balance problems, falls, difficulty with buttons, handwriting, or walking. ^[4]
• Sudden onset or symptoms interfering with daily function this may warrant treatment adjustments to prevent irreversible nerve damage. ^[4]

---

How neuropathy is managed

Management aims to reduce symptoms, protect function, and maintain cancer therapy when safe.

Treatment adjustment

• Dose reduction, treatment delay, or switching to a less neurotoxic regimen are common strategies when symptoms rise to moderate or severe levels. ^[1] Early recognition helps avoid irreversible injury. ^[4]

Symptom‑relief medicines

• Duloxetine is often considered for painful neuropathy symptoms. While evidence varies by drug class, it’s one of the better‑supported options for CIPN‑related pain relief. [PM18]
• Other agents (e.g., gabapentinoids, topical therapies) may be considered case‑by‑case, though guideline support is mixed and benefits can be modest. [PM18]

Rehabilitation and safety

• Physical and occupational therapy can improve balance, strength, dexterity, and reduce fall risk, even during active cancer care. ^[9] Conventional rehab approaches remain effective and should be tailored to each person’s functional needs. ^[10]
• Fall prevention: home safety review, footwear with good grip, assistive devices as needed. ^[9]
• Exercise: gentle, regular activity to maintain strength and sensory feedback; supervised programs may help. ^[9]

Self‑care tips

• Protect hands and feet: avoid extreme heat/cold; check skin for injuries when sensation is reduced. ^[11]
• Foot care: cushioned shoes, orthotics if needed, and regular foot checks to prevent ulcers. ^[11]
• Daily adjustments: use tools with larger grips, organize spaces to reduce tripping hazards, and take breaks to prevent overuse. ^[11]

---

Special considerations by treatment type

• Taxanes/platins: monitor closely after each cycle; cumulative risk is substantial. ^[1]
• Vinca alkaloids (vincristine): heightened vigilance due to higher incidence; dose caps and careful titration may reduce risk. ^[5]
• ADCs (e.g., enfortumab vedotin, ado‑trastuzumab emtansine): sensory neuropathy is common but often low‑grade; median onset around 2–3 months; adjust therapy if ≥grade 2 symptoms persist. ^[7]
• Immunotherapy: immune‑related neuropathies can occur; follow specific irAE management pathways if suspected. ^[5]

---

What to discuss with your oncology team

• Symptom timeline and triggers: when tingling or pain started, activities that worsen it. ^[6]
• Functional impact: balance issues, falls, or difficulty with daily tasks. ^[4]
• Treatment plan options: dose changes, schedule adjustments, or alternative agents. ^[1]
• Supportive care: referral to rehabilitation, pain management, and strategies for home safety. ^[9]

---

Bottom line

Neuropathy is a common, often dose‑related side effect of several cancer treatments, especially taxanes, platins, vinca alkaloids, and certain antibody‑drug conjugates. Early recognition and collaborative management combining treatment adjustments, symptom‑relief medications, and rehabilitation can meaningfully reduce symptoms and help preserve quality of life. ^[1] Because some neuropathy can become irreversible, reporting symptoms early allows safer, more personalized decisions about ongoing therapy. ^[4]

---

궁금한 점 있으면 언제든 퍼슬리에 물어보세요